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Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family that
induces cancer cell death by apoptosis with some selectivity. TRAIL-induced apoptosis is mediated by the
transmembrane receptors death receptor 4 (DR4) (also known as TRAIL-R1) and DR5 (TRAIL-R2). TRAIL
can also bind decoy receptor 1 (DcR1) (TRAIL-R3) and DcR2 (TRAIL-R4) that fail to induce apoptosis since
they lack and have a truncated cytoplasmic death domain, respectively. In addition, DcR1 and DcR2 inhibit
DR4- and DR5-mediated, TRAIL-induced apoptosis and we demonstrate here that this occurs through distinct
mechanisms. While DcR1 prevents the assembly of the death-inducing signaling complex (DISC) by titrating
TRAIL within lipid rafts, DcR2 is corecruited with DR5 within the DISC, where it inhibits initiator caspase
activation. In addition, DcR2 prevents DR4 recruitment within the DR5 DISC. The specificity of DcR1- and
DcR2-mediated TRAIL inhibition reveals an additional level of complexity for the regulation of TRAIL
signaling.
Apoptosis is one of the death phenotypes that can be trig-
gered in tumor cells by anticancer agents. Resistance of tumor
cells to apoptosis can account for treatment failure (18). One
of the stimuli that can induce tumor cell death by apoptosis is
the member of the tumor necrosis factor superfamily known as
TRAIL (tumor necrosis factor-related apoptosis-inducing li-
gand) (16). TRAIL has gained considerable interest in oncol-
ogy since it displays specific antitumoral activity against a wide
range of tumor cells (14, 41, 47) without significant side effects,
at least in mice and monkeys (3, 21, 22).
TRAIL triggers apoptosis upon engagement of one of its
two agonistic receptors, named DR4 (death receptor 4) (33)
and DR5 (death receptor 5) (7, 46). In response to TRAIL,
these receptors recruit the adaptor protein FADD (Fas-asso-
ciated death domain), through death domain homophilic in-
teractions (5), and the initiators procaspase-8 and -10, through
death effector domain interactions with FADD, hence forming
the macromolecular complex called DISC (death-inducing sig-
naling complex). Within this complex, procaspase-8 and -10
are activated by autoproteolytic cleavage and initiate the
caspase cascade leading to apoptosis (42).
In addition to the agonistic TRAIL receptors DR4 and DR5,
TRAIL can bind to related but antagonistic receptors, includ-
ing TRID or TRAIL-R3 (11, 27, 32) and TRUNDD or
TRAIL-R4 (10), also coined DcR1 (decoy receptor 1) and
DcR2 (decoy receptor 2), respectively. DcR1 is characterized
by the presence of a glycosylphosphatidylinositol membrane
anchor and therefore has no intracellular domain, whereas the
death domain of DcR2 is truncated. Transient overexpression
of DcR1 or DcR2 in TRAIL-sensitive tumor cells prevents cell
death triggering by TRAIL (10, 11), and recent evidence indi-
cates that tumor and normal cells can acquire resistance to
TRAIL-induced killing by up-regulating TRAIL antagonistic
receptors (6, 8, 9, 34).
Upon TRAIL binding, DcR1 and DcR2 fail to recruit
FADD and, consequently, fail to induce downstream cell sig-
naling events leading to apoptosis (10, 32). Initial binding ex-
periments suggested that TRAIL binding affinities to TRAIL
agonistic and antagonistic receptors were similar (11, 24), but
subsequent studies demonstrated that DcR1 and DcR2 affin-
ities to TRAIL were lower than that of DR4 or DR5 (8). To
date, the molecular mechanisms by which DcR1 and DcR2
confer resistance to TRAIL-induced apoptosis remain unclear
(1, 6, 9, 13).
In the current study, we demonstrate that DcR1 and DcR2
inhibit TRAIL-induced apoptosis by distinct mechanisms.
DcR1 acts merely as a competitor for TRAIL binding, pre-
venting DR5-associated DISC assembly, while DcR2 impairs
TRAIL DISC processing and initiator caspase activation.
DcR2 interacts with DR5 in the native DISC in a TRAIL-
dependent manner and prevents DR4 corecruitment to DR5.
MATERIALS AND METHODS
Ligand production and antibodies. Flag-tagged recombinant soluble human
TRAIL and his-tagged TRAIL were produced and used as described previously
(37). Flag-FasL was purchased from Axxora (San Diego, CA). Anti-Flag (M2)
was purchased from Sigma-Aldrich (St. Quentin Fallavier, France). For Western
blotting experiments, anti-DR4, anti-DR5, anti-DcR1, and anti-DcR2 antibodies
were purchased from Chemicon (Temecula, CA), anti-FADD and anti-flotillin-1
were obtained from Transduction Laboratories (Lexington, KY), anti-caspase-8
and -10 were obtained from Medical and Biological Laboratories (Nagoya, Ja-
pan), and anti-FLIP was obtained from Alexis (Coger, Paris, France). Anti-
caspase-3 was purchased from Cell Signaling (Ozyme, Saint Quentin Yvelines,
France) and anti-poly(ADP-ribose) polymerase (anti-PARP) from Boehringer
Mannheim (Germany). For flow cytometry experiments with Jurkat, HeLa, and
HepG2, anti-DR4 (wB-K32), anti-DR5 (B-L27), anti-DcR1 (wB-B44), and anti-
DcR2 (wB-P30) were kindly provided by Diaclone (Besanc¸on, France). Fluores-
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FIG. 1. Inhibition of TRAIL-induced cell death by decoy receptors. (A) Jurkat (J) and HeLa (H) cells, stably transduced with retroviruses
encoding DR4, DcR1, DcR2, or the empty vector pMSCV (CTR), were analyzed by fluorescence-activated cell sorter staining for TRAIL receptor
expression as indicated. (B) Cellular viability in the different Jurkat cell populations was evaluated by PMS/MTS after a 24-h treatment with
increasing concentrations of cross-linked recombinant Flag-tagged soluble TRAIL or FasL. (C) Cellular viability of HeLa cell populations was
evaluated as described above by use of the methylene blue assay. (D) Jurkat and HeLa cell populations were stimulated for 6 h with Flag-TRAIL
(100 ng/ml), alone or in combination with zVAD-fmk (100 M) or with the agonistic anti-DR5 antibody (100 g/ml), and apoptosis was determined
by Hoechst staining. Data (means  standard deviations) correspond to the percentage of apoptotic nuclei among the total nuclei counted (n 
3). Data are representative of at least three independent experiments.
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cein isothiocyanate-coupled goat anti-mouse secondary antibody was obtained
from Molecular Probes (Invitrogen, Cergy Pontoise, France). For flow cytometry
experiments with monocytes, phycoerythrin-conjugated anti-DR4 (B-N36), anti-
DR5 (B-K29), anti-DcR1 (B-D44), and anti-DcR2 (B-R27) were provided by
Diaclone. Anti-CD14 coupled to phycoerythrin was purchased from Pharmingen
(BD Biosciences, California). For immunoprecipitation, the goat anti-caspase-8
(C20) antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA),
and the anti-DR5 (B-D37) and anti-DcR2 (wB-P30) antibodies were obtained
from Diaclone. For cytotoxic assays, the agonistic anti-DR5 antibodies (B-T28
for Jurkat cells and B-D37 for HeLa and HepG2 cell lines) were provided by
Diaclone.
Cell culture. The HeLa (human cervix carcinoma) cell line was cultured with
high-glucose Dulbecco’s modified Eagle’s medium (Sigma-Aldrich) supple-
mented with 10% fetal calf serum (Gibco-BRL, Erigny, France) and penicillin-
streptomycin (100 g/ml of each). The Jurkat (human T-lymphoma) cells were
cultured in RPMI 1640 medium (BioWhittaker Co., Fontenay-sous-bois, France)
containing 10% of fetal calf serum and penicillin-streptomycin. The HepG2
(human hepatocarcinoma) cell line was cultured in 50% Ham’s F-12 medium
(BioWhittaker Co.) and 50% Dulbecco’s modified Eagle’s medium, supple-
mented with 5% fetal calf serum and penicillin-streptomycin. All cell lines were
grown in 5% CO2 at 37°C. Monocytes were purified from peripheral blood
mononuclear cells of healthy donors by use of a monocyte purification kit (Miltenyi
Biotec, California).
Retrovirus production and cell transduction. The retroviral vector pMSCV-
puro and the generation of viruses have previously been described (30). DR4,
DcR1, and DcR2 full-length constructs were subcloned from pCR-3 vector
(Invitrogen) to pMSCV-puro. HeLa and Jurkat cells were transduced for 16 h
with viral supernatants containing polybrene (8 g/ml), washed in phosphate-
buffered saline (PBS), and cultured in complete medium containing puromycin
(2.5 g/ml).
Measurement of cell viability and apoptosis. In 96-well plates, 104 cells were
incubated at 37°C for 24 h with increasing concentrations of his-TRAIL or
Flag-FasL (from 0 to 10,000 ng/ml). For Jurkat cells, cell viability was determined
by the PMS/MTS method, according to the manufacturer’s specifications (Pro-
mega, Madison, Wis.), while cell viability was determined by methylene blue for
HeLa cells (30). Apoptosis was assessed by Hoechst staining by determining the
percentage of condensed nuclei from at least 300 cells per condition. When
indicated, cells were additionally treated with 50 M zVAD-fmk (Sigma-
Aldrich).
Immunoprecipitations. For TRAIL DISC analysis, 108 cells were stimulated
with 5 g of Flag-TRAIL cross-linked with 10 g anti-Flag M2 in 1 ml medium
for the indicated times at 37°C. Cells were then washed with cold PBS and lysed
in 1 ml lysis buffer containing 1% of detergent (NP-40 or Brij 78), 20 mM of
Tris-HCl (pH 7.5), 150 mM of NaCl, and 10% of glycerol. Lysates were pre-
cleared with Sepharose 6B (Sigma-Aldrich) and immunoprecipitated overnight
at 4°C with protein G-Sepharose beads (Amersham Biosciences, Les Ullis,
France). For caspase-8 or TRAIL receptor immunoprecipitations, cells were
stimulated as described above with 5 g/ml His-TRAIL and lysed in NP-40-
containing lysis buffer, and lysates were precleared before 5 g of immunopre-
cipitating antibody was added. In both cases, beads were then washed four times
with the respective detergent, and immunoprecipitates were eluted in lysis buffer
before being processed for immunobloting.
Lipid raft isolation. Lipid rafts were isolated by sucrose density gradient
centrifugation as previously described (50). Cells (108) were stimulated or not
stimulated with 5 g of His-TRAIL for 1 h at 37°C, washed in PBS, lysed on ice
for 20 min in 1 ml of MNX buffer (1% of Triton X-100 in 25 mM of MES
FIG. 2. Inhibition of caspase activation in decoy receptor-expressing cells. Jurkat cell populations were treated with 100 ng/ml of His-TRAIL,
alone or combined with 50 M zVAD-fmk (), for the indicated time periods. Cells were subsequently analyzed by Hoechst to determine the
percentage of apoptosis (bottom), and the corresponding cellular lysates were analyzed by Western blotting using anti-caspase and anti-PARP
antibodies, as described in Materials and Methods. Anti-caspase-7 and -8 antibodies recognizing caspase-7 (p43) and -8 (p18) active fragments are
indicated by asterisks. Caspases cleavage products and PARP fragments are indicated by black arrows.
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[morpholineethanesulfonic acid], 150 mM of NaCl, pH 6.5) supplemented with
protease inhibitor cocktail (Roche Molecular Biochemicals, Meylan, France),
and homogenized (10 strokes) with a loose-fitting glass Dounce homogenizer
(Polylabo, Illkirch, France). The homogenates were mixed with 2 ml of 90%
sucrose made with MNX buffer and placed on the bottom of a centrifuge tube.
The samples were then overlaid with 4 ml of 35% sucrose and 4 ml of 5% sucrose
and centrifuged at 175,000  g for 20 h at 4°C. One-milliliter fractions were
collected from the top of the gradient and analyzed by Western blotting or
enzyme-linked immunosorbent assay (ELISA). The proteins of the different
fractions obtained from monocytes were precipitated by 5% trichloroacetic acid
before ELISAs. Cholesterol quantification was assessed by use of the Amplex
Red cholesterol assay kit (Molecular Probes).
Western blotting. Immunoprecipitates were resolved by sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis and transferred to nitrocellulose mem-
branes. Nonspecific binding sites were blocked by incubation in PBS containing
0.05% Tween 20 and 5% powdered milk. Immunoblots were then incubated with
specific primary antibody, followed by horseradish peroxidase-conjugated sec-
ondary antibody, and were developed by the enhanced chemiluminescence
method according to the manufacturer’s protocol (Pierce, Rockford, IL).
ELISA. TRAIL or DcR1 protein content in the different fractions obtained
after lipid raft isolation was quantified by ELISA according to the manufacturer’s
instructions (Diaclone).
RESULTS
DcR1 and DcR2 expression inhibits TRAIL-induced apop-
tosis. TRAIL decoy receptors are expressed at low levels on
the surface of most tumor cell lines, and when spontaneously
present, their level of expression at the surface of a given cell
line varies (not shown). In order to analyze the molecular
mechanisms involved in the inhibition of TRAIL-induced cell
death by these decoy receptors in a stable model system, we
transduced the TRAIL-sensitive cell lines Jurkat and HeLa
with retroviral expression vectors for DcR1 and DcR2. Com-
pared to conventional transfections, the retroviral gene trans-
fer enables a stable, reproducible, and limited expression of
the gene.
In line with previous reports (6, 10, 34, 36), overexpression
of DcR1 or DcR2 at the cell surface (Fig. 1A) inhibited
TRAIL-induced cell death (Fig. 1B and C). DcR1 and DcR2
were nearly as efficient as the pan caspase inhibitor zVAD-fmk
at inhibiting TRAIL-induced apoptosis (Fig. 1D). All the cell
populations remained sensitive to death induced by Flag-FasL
(Fig. 1B and C) and to an agonistic monoclonal antibody
targeting DR5 (Fig. 1D).
Analysis of caspase activation by use of caspase fluorogenic
substrates (not shown) or by Western blotting (Fig. 2) revealed
that both DcR1 and DcR2 inhibited early events of TRAIL
signaling, as witnessed by the obvious reduction in caspase-8
and caspase-10 activation in cells expressing these receptors.
As a consequence, activation of the effector caspases, caspase-3,
-6, and -7, or cleavage of the downstream target PARP was
severely impaired. Similar results were obtained with HeLa cell
populations (not shown).
Expression of DR4 in the Jurkat cell line that spontaneously
expresses only DR5 (Fig. 1A) did not increase cell sensitivity to
TRAIL (Fig. 1B), probably because Jurkat cells are already
highly sensitive to TRAIL-induced cell death.
DcR1 and DcR2 differentially inhibit TRAIL DISC forma-
tion. Since the protective effects of decoy receptors appear to
be an upstream event during caspase activation, TRAIL DISC
composition was analyzed by coimmunoprecipitation and im-
munoblotting using cross-linked recombinant Flag-tagged sol-
uble TRAIL. In line with earlier reports (5), TRAIL DISC
assembly in Jurkat cells involved the agonistic receptor DR5,
the adaptor protein FADD, and caspase-8 (Fig. 3A). The same
was true for HeLa cells, except that in addition, the endoge-
nous DR4 coimmunoprecipitated with DR5 in a ligand-depen-
dent manner (Fig. 3B).
In both Jurkat and HeLa cell populations, TRAIL DISC
compositions differed significantly, depending on which decoy
receptor was expressed. In DcR2-expressing cell populations,
both DcR2 and DR5 coimmunoprecipitated with TRAIL (Fig.
3A and B). In contrast, DR4, whose expression was observed
only in HeLa cells, was not identified in the DISC (Fig. 3B).
The recruitment of procaspase-8 to the DISC was unaffected
by DcR2, but its activation was impaired as there was little
cleavage of procaspase-8 (Fig. 3). These results in addition to
FIG. 3. DcR1 and DcR2 differentially affect TRAIL DISC forma-
tion. (A) Jurkat and (B) HeLa cell populations were stimulated with 5
g/ml Flag-TRAIL in the presence of 10 g/ml of M2 cross-linking
antibody for the indicated time periods (see Materials and Methods).
After cell lysis in NP-40-containing buffer, the DISC was immunopre-
cipitated (IP) and analyzed by Western blotting using antibodies to
DR4, DR5, DcR1, DcR2, FADD, and caspase-8. Caspase-8 cleavage
product, corresponding to the p43 fragment, is indicated by black
arrowheads. Molecular masses are in kDa. Data are representative of
at least three independent experiments.
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those shown in Fig. 1 suggested that DcR2 could inhibit
caspase-8 processing within the DISC and thus impair TRAIL-
induced cell death.
DISC analysis of cell populations expressing DcR1 provided
strikingly different results. DISC assembly was severely inhib-
ited by DcR1 expression, as only small amounts of DISC com-
ponents were immunoprecipitated (Fig. 3A and B). In addition,
under experimental conditions using NP-40 as a detergent, DcR1
was not immunoprecipitated by TRAIL. The glycosylphosphati-
dylinositol-anchored structure of DcR1 (39) suggested that the
molecule could localize within lipid raft structures. We used Tri-
ton X-100 detergent and sucrose density gradient (25) to isolate
these structures whose identification was checked by immuno-
blotting for the lipid raft-associated protein flotillin-1 (Fig. 4A and
B) and by measuring the cholesterol content in each fraction (Fig.
4C and D). When expressed in HeLa and Jurkat cells, DcR1
localized mainly within lipid rafts, whereas DR4 (not shown),
DR5, and DcR2 did not (Fig. 4A and B). TRAIL stimulation
induced partial translocation of DR5 in lipid raft structures, but
this redistribution occurred independently of DcR1 or DcR2 ex-
pression (Fig. 4A and B).
The localization of DcR1 within raft microdomains was con-
sistent with the insolubility of DcR1 in a lysis buffer containing
NP-40 detergent (Fig. 4E). We therefore used Brij78, a deter-
gent in which lipid rafts are solubilized (2), to reanalyze the
DISC induced by TRAIL in DcR1-expressing Jurkat cells.
Under these conditions, DcR1 coimmunoprecipitated with
TRAIL but the other DISC components were hardly detect-
FIG. 4. DcR1 inhibits TRAIL-DISC formation in lipid rafts. (A) Jurkat and (B) HeLa cell populations were left untreated or stimulated for
1 h with 100 ng/ml of His-TRAIL, lysed in Triton X-100, and subjected to density gradient fractionation. Fractions corresponding to lipid rafts
(R) and soluble proteins (S) were immunoblotted for DR5, DcR1, DcR2, and flotillin-1 as indicated. Data are representative of at least three
independent experiments. Fractions were analyzed for cholesterol content in Jurkat (C) and (D) HeLa cells by use of the Molecular Probes Amplex
Red cholesterol assay kit. (E) TRAIL DISC formation in Jurkat cell populations was analyzed after Flag-TRAIL stimulation and immunopre-
cipitation (IP) in the presence of the M2 anti-Flag antibody as in Fig. 2, for the indicated time, from cell lysates in (E) NP-40- or (F) Brij78-
containing lysis buffer. (G) Analysis of TRAIL protein content from density sucrose gradient fractions obtained from Jurkat cells treated or not
treated with His-TRAIL, as described for panel A, was performed by use of an ELISA kit obtained from Diaclone (see Materials and Methods).
(H) Freshly isolated monocytes were analyzed by fluorescence-activated cell sorter staining for CD14 and TRAIL receptor expression as indicated.
(I) DcR1 protein content from freshly isolated monocytes was analyzed by use of a DcR1 ELISA kit from Diaclone after density sucrose gradient
fractionation. Lipid rafts (R) and soluble protein fractions (S) are indicated. (J) Monocytes were stimulated with His-TRAIL as described for panel
A, and TRAIL was measured by ELISA, as described above, in lipid rafts (R) and soluble protein fractions (S) as indicated.
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able in the cell population (Fig. 4F). Analysis of TRAIL dis-
tribution in unstimulated Jurkat cells or in Jurkat cells treated
with recombinant TRAIL, in the fractions collected by sucrose
gradient density, clearly indicated that a considerable amount
of exogenous TRAIL was sequestered into lipid raft fractions
in cells expressing DcR1, yet was absent from these fractions in
control cells or cells expressing DcR2 (Fig. 4G). These results
were confirmed in monocytes, which were recently shown to
express DcR1 endogenously (44). In these cells, both DR5 and
DcR1 are expressed (Fig. 4H), and DcR1 is localized mainly
within rafts (Fig. 4I). According to the above results, upon
stimulation, a significant fraction of recombinant TRAIL is
sequestered in lipid rafts (Fig. 4J). Altogether, these results
suggested that the expression of DcR1 could prevent DISC
formation by titrating TRAIL within lipid rafts.
DcR2 is recruited to the DR5-containing complex, where it
inhibits activation of apical caspases. TRAIL DISC formation
in HeLa cells was further analyzed by immunoprecipitation
using antibodies targeting caspase-8, DR5, or DcR2. Immuno-
precipitating caspase-8 after TRAIL stimulation enabled the
pull-down of DISC components, including DR4, DR5, and
FADD as well as the initiator caspase-10, in control HeLa cells
(Fig. 5A). In line with experiments whose results are shown
in Fig. 3, few DISC components were pulled down by im-
munoprecipitating caspase-8 from DcR1-overexpressing
cells (Fig. 5A). In HeLa cells overexpressing DcR2, how-
ever, in addition to DcR2 and similar to TRAIL immuno-
precipitation, caspase-8 immunoprecipitation also pulled
down larger amounts of caspase-10 (Fig. 5A). This increase in
caspase-8-associated caspase-10 could be the consequence of a
reduced DISC processing activity. Accordingly, few caspase-10
cleavage products are found in DcR2-expressing cells com-
pared to those found in control cells after TRAIL stimulation
(Fig. 2). Caspase-10 activity as measured by fluorogenic sub-
strates is also highly reduced in these cells (not shown). Similar
findings have been documented for cells knocked down for the
caspase-8 regulator c-FLIP (38). Immunoprecipitation of
caspase-8 also confirmed that the presence of DcR2 within the
caspase-8-containing complex partially excluded DR4 from the
TRAIL-induced DISC (Fig. 3B and 5C).
The stoichiometry of TRAIL receptors within the DISC
remains poorly understood, but indications exist that decoy
receptors might interact with agonistic receptors (8, 24). To
determine whether the receptors were present in unique or
distinct complexes, we used anti-DR5 and anti-DcR2 antibod-
ies to immunoprecipitate TRAIL DISC components. In
TRAIL-treated control HeLa cells, immunoprecipitation with
an anti-DR5 antibody indicated that DR5 and DR4 were
within the same complex (Fig. 5B), together with FADD and
caspase-10 and its cleavage products (Fig. 5B), while in DcR1-
expressing HeLa cells, few DISC components associated to
DR5 (Fig. 5B). When performed with HeLa cells expressing
DcR2, the same experiments indicated for the first time that
DcR2 could interact with DR5 in a ligand-dependent manner
FIG. 4—Continued.
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and confirmed the exclusion of DR4 from DR5 complexes
containing DcR2 (Fig. 3B and 5C).
These experiments also confirmed that in the presence of
DcR2, the amount of caspase-10 associated with the DISC
components was increased (Fig. 5B). In addition, the use of an
anti-DcR2 antibody strengthened the finding that DcR2 asso-
ciates with DR5 in a ligand-dependent manner (Fig. 5C).
Endogenous DcR2 interacts with DR5 to inhibit DISC acti-
vation. To confirm the finding that DcR2 interacts with DR5
via TRAIL in cells expressing endogenous levels of DcR2, we
used the TRAIL-resistant HepG2 cell line that expresses DR4,
DR5, DcR2, and, for a minor subpopulation only, DcR1 (Fig.
6A). In HepG2, stimulation with TRAIL triggered the forma-
tion of a DISC containing DR5, DcR2, FADD, and the initi-
ators caspase-8 and -10 as seen by TRAIL immunoprecipi-
tation. Similar to the results obtained using HeLa cells
expressing DcR2, DR4 was not recruited into the DISC in
HepG2 cells stimulated by TRAIL (Fig. 6B). In addition,
DISC analysis using the anti-DR5 or anti-DcR2 antibodies
provided similar information. Accordingly, quite substantial
amounts of procaspase-10 were still detected within the DISC,
and the ligand-dependent interaction of DcR2 with DR5 in
FIG. 5. DcR2 allows TRAIL-DISC formation but prevents its activation. (A) HeLa cell populations were stimulated with 5 g/ml recombinant
His-TRAIL for the indicated time periods. After cell lysis, DISCs were immunoprecipitated (IP) with an anti-caspase-8 (casp-8) antibody and
analyzed by immunoblotting using antibodies to DR4, DR5, DcR1, DcR2, FADD, caspase-8, and caspase-10. (B) HeLa cell populations were
stimulated as described above, and DISC analysis was performed using the anti-DR5 antibody or an isotype control. (C) The DcR2-expressing
HeLa cell population was stimulated as described for panel A, and DISC analysis was performed using an anti-DcR2 antibody. Caspase-8 and
caspase-10 cleavage products are indicated by black arrowheads.
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these cells was confirmed (Fig. 6B). Altogether, these data
demonstrate that DcR2 is able to interact with DR5 within the
DISC, where it inhibits initiator caspase activation.
DISCUSSION
The selective toxicity of TRAIL against tumor cells makes it an
attractive candidate for treating cancers. However, all tumor cells
are not equally sensitive to this cytokine. Identification of the
molecular mechanisms that modulate the response to TRAIL
may help to select those tumors that may optimally respond to
this therapeutic approach. A first resistance mechanism is related
to the lack of expression of DR4 and DR5 at the surface of some
cancer cells (15). TRAIL-induced apoptosis has also been dem-
onstrated to be inhibited by a number of intracellular regulators,
such as proteins from the IAP and Bcl-2 families (48) and c-FLIP
(19). The role of TRAIL decoy receptors in inducing tumor re-
sistance towards TRAIL-induced cell death is now well estab-
lished (12, 23, 39, 51). However, how these receptors prevent
TRAIL-induced apoptosis is less clear. Our results provide, for
the first time, strong evidence that the molecular mechanisms
involved in TRAIL-induced cell death inhibition by DcR1 and
DcR2 differ in important ways.
We provide strong evidence that DcR1, which localizes in
sphingolipid- and cholesterol-enriched membranes, structures
also known as raft microdomains, inhibits TRAIL-induced cell
death merely by competition. In both Jurkat and HeLa cells
FIG. 6. Endogenous DcR2 prevents TRAIL-DISC processing. (A) HepG2 cells were analyzed by fluorescence-activated cell sorter staining for
TRAIL receptor expression as indicated. (B) HepG2 cells were stimulated as described for Fig. 2 for DISC analysis (IP TRAIL/M2). Alternatively,
cells were stimulated with His-TRAIL as described for Fig. 5 and DISC analysis was performed using either the anti-DR5 or the anti-DcR2
antibody. Immunoprecipitations (IP) were then analyzed by immunoblotting using antibodies to DR4, DR5, DcR1, DcR2, FADD, caspase-8, and
caspase-10.
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engineered to express this decoy receptor, DcR1 bound
TRAIL efficiently and impaired DISC assembly, as demon-
strated by TRAIL immunoprecipitation using Brij78, a deter-
gent that solubilizes lipid rafts (2). A significant fraction of
recombinant TRAIL was sequestered into lipid rafts, as mea-
sured by ELISA, both in Jurkat cells engineered to express
DcR1 and in HeLa cells (not shown) but also in monocytes
that express endogenous levels of DcR1 at the cell surface.
These findings are consistent with the current view that DcR1
is a decoy receptor that inhibits TRAIL-induced cell death by
the competitive binding of TRAIL.
DcR2, on the other hand, allowed DR5-mediated DISC
formation but prevented initiator caspase activation within the
DISC. Using different antibodies targeting specifically DR5 or
DcR2 to analyze TRAIL DISC composition, we show that the
interaction of DcR2 with DR5 is mediated by TRAIL (Fig. 5C
and 6B). Yet, recent findings indicate that the spontaneous
ligand-independent interaction of DcR2 with DR5 which oc-
curs through the PLAD (pre-ligand-associated domain) is re-
quired for the inhibition of TRAIL-induced cell death (8).
These conclusions are in sharp contrast to our demonstration
that the interaction of DcR2 with DR5 is indirect and is me-
diated by TRAIL. One possible explanation for this discrep-
ancy could be that the PLAD-dependent interaction of DcR2
with DR5 prior to exogenous TRAIL stimulation is triggered
either by endogenous soluble secreted TRAIL or by mem-
brane-bound-expressed TRAIL in Jurkat cells. This hypothe-
sis, however, remains to be tested.
How DcR2 inhibits caspase-8 and -10 processing remains to
be determined. The prevailing view of TRAIL DISC assembly
is based on homophilic homodimerization or homotrimeriza-
tion of either the death domain or the death effector domain
(49). Here, we show that DcR2 and DR5 form a heteromeric
complex upon TRAIL binding. As initiator caspases were re-
cently shown to be activated by dimerization (4, 31), DcR2,
which is devoid of a functional death domain, might disrupt the
DISC arrangement and prevent activation of caspase-8 and -10
by loosening the docking structure. It is very likely that the
significant increase in procaspase-10 content in the DcR2-
containing DISC is due to the impaired activation of caspase-8,
as caspase-10 is unable to substitute for caspase-8 in cell death
triggered by TRAIL (40).
The heteromeric complex that forms in response to TRAIL
in DcR2-expressing cells could also change the composition of
the DISC. In our hands, no obvious change in c-FLIP or
FADD recruitment was observed in any of the tested cell lines
(not shown). We did not identify any spontaneous association
of c-FLIP to DR5, contrary to recent findings on Jurkat cells
(17). The only change identified in the DISC composition of
TRAIL-stimulated DcR2-expressing cells was the inhibition of
DR4 recruitment to the DISC. As DcR2 inhibits TRAIL-
induced cell death both in Jurkat cells, devoid of DR4, and in
HeLa cells that express DR4, the lack of DR4 recruitment
within the DISC may not account for the DcR2-mediated
inhibition of TRAIL signaling. DR5 may prevail over DR4 to
signal TRAIL-induced apoptosis in Jurkat cells, as ectopic
expression of DR4 does not change cell sensitivity to TRAIL.
However, this might not reflect the situation in all cell lines.
The prevalence of either DR4 or DR5 for the triggering of the
TRAIL cell death process has been demonstrated in different
cell types (20, 28). Therefore, in addition to its ability to impair
initiator caspase activation, DcR2-mediated DR4 exclusion
from the DISC could also play an important role in regulating
sensitivity to TRAIL-induced cell death depending on the cell
type.
In addition, since DcR2 impairs caspase-8 and -10 process-
ing within the TRAIL DISC, the question arises as to whether
DcR2 could play a role in the triggering of TRAIL nonapop-
totic functions. We have shown previously that active pro-
caspases that are retained in the DISC may fail to activate a
proapoptotic pathway, yet could cleave other substrates close
to the DISC and participate in nonapoptotic signaling path-
ways due to changes in caspase-8, caspase-10, and c-FLIP ra-
tios (31). Recent evidence indicates that TRAIL is involved in
human intestinal differentiation, and interestingly, DcR1 and
DcR2 have been shown to be up-regulated and expressed at
the cell surface during the process (35). Whether DcR1 and
DcR2 participate in this nonapoptotic event, e.g., by enhancing
the formation of the recently described secondary complex that
activates various kinases (43), remains to be determined.
Lastly, the understanding of the molecular mechanisms of
TRAIL-mediated apoptosis inhibition by decoy receptors
could be an important issue in oncology since chemotherapeu-
tic drugs are known to sensitize tumor cells to TRAIL-induced
apoptosis (29, 45). However, recent evidence indicates that cell
surface expression of DcR2 could compromise not only
TRAIL-induced cell death but also apoptosis induced by che-
motherapeutic drugs (26). Therefore, further studies will be
needed to determine whether TRAIL decoy receptors might
affect antitumoral approaches aimed at combination therapy
involving agents that target TRAIL or TRAIL derivatives, such
as the newly developed anti-DR4 and anti-DR5 agonistic an-
tibodies.
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